Tuesday Morning Corporation (TUES), Swift Transportation Co (SWFT), Amicus Therapeutics, Inc. (FOLD): Citadel’s Latest Moves

According to our database, two other prominent stockholders of Tuesday Morning Corporation (NASDAQ:TUES) are Donald Chiboucis‘ Columbus Circle Investors and Phil Gross and Robert Atchinson’s Adage Capital Management.

Citadel’s second move was to substantially bump its stake in Swift Transportation Co (NYSE:SWFT) by acquiring some 3.63 million shares of the company, which put the total holding at about 4.90 million shares. The new holding represents 5.4% of the $3.58 billion company’s outstanding stock. The stock of Swift Transportation Co (NYSE:SWFT) has depreciated by nearly 12.29% year to date. The company’s sizable leverage is a cause for concern for its investors, which has its origins in the 2007 leverage buyout of Swift Transportation Co (NYSE:SWFT). While it has been possible to meet the targets for reducing debt in the prevailing low interest rates environment, the future might hold some unpleasant surprises, especially considering the company’s announcement that it has to increase wages again in 2015 in order to keep its truck drivers.

Among the billionaires that we track, five had investments totaling $183.18 million in the company at the end of 2014. Israel Englander is one of them and his fund Millennium Management held about 2.9 million shares of Swift Transportation Co (NYSE:SWFT).

Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s stake in Citadel’s portfolio was increased by 2.58 million shares to 4.93 million shares. The current holding represents 5.1% of the company’s outstanding stock. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has had a nice run this year and the stock is up by about 28.85% since the beginning of the year. The $1.02 billion biopharmaceutical company’s treatment for Fabry disease, Migalastat was approved for an accelerated schedule by both FDA and its European counterpart, EMA, in March.

A total of 26 hedge funds, among those that we track, had an aggregate investment of $382.56 million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) at the end of the fourth quarter, as compared to 23 funds with $155.33 million in the previous quarter. Joseph Edelmen’s Perceptive Advisors was the largest shareholder among these funds as of the end of 2014.

Disclosure: None